Tags

Type your tag names separated by a space and hit enter

Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Int J Biol Markers. 2019 Dec; 34(4):398-405.IJ

Abstract

OBJECTIVE

To investigate the role of programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and P16 in patients with head and neck squamous cell carcinoma (HNSCC).

METHODS

A total of 95 paraffin-embedded samples of tumorous tissue of HNSCC were collected. Expression levels of PD-1, PD-L1, and P16 were determined by immunohistochemistry.

RESULTS

A significantly higher proportion of PD-1 among patients infected with the human papillomavirus was found. PD-L1 expression is closely associated with the primary site of the tumor, postoperative recurrence, survival, PD-1 expression and P16 expression. Univariable analysis indicated that T stage, N stage, tumor node metastasis stage, tumor differentiation, and PD-L1 expression were all shown to be prognostic variables for overall survival in patients with HNSCC. In the multivariate analysis, only N stage (P = 0.010) and PD-L1 expression (P = 0.001) were found to be independent prognostic variables for overall survival. In addition, for disease recurrence, multivariate analysis showed that only PD-L1 expression was the associated independent risk factor. For the patients with negative PD-L1 expression, Kaplan-Meier analysis revealed that they had significantly worse outcomes in terms of overall survival (P = 0.001). Similarly, compared with the patients with positive PD-L1 expression, those with negative PD-L1 expression had a higher probability of recurrence (P = 0.026).

CONCLUSIONS

The expression of PD-L1, PD-1, and P16 in HNSCC is significantly correlated. Human papillomavirus infection (P16 positive) is negatively related to postoperative recurrence. HNSCC patients with positive PD-L1/PD-1 expression tend to have better overall survival outcomes and lower probability of recurrence, providing more evidence for the PD-l-targeted immunotherapy of HNSCC.

Authors+Show Affiliations

Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Department of Surgical Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. State Key Laboratory of Oncology in South China, Guangzhou, China. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31674884

Citation

Chen, Shu-Wei, et al. "Expression of PD-1/PD-L1 in Head and Neck Squamous Cell Carcinoma and Its Clinical Significance." The International Journal of Biological Markers, vol. 34, no. 4, 2019, pp. 398-405.
Chen SW, Li SH, Shi DB, et al. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int J Biol Markers. 2019;34(4):398-405.
Chen, S. W., Li, S. H., Shi, D. B., Jiang, W. M., Song, M., Yang, A. K., Li, Y. D., Bei, J. X., Chen, W. K., & Zhang, Q. (2019). Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. The International Journal of Biological Markers, 34(4), 398-405. https://doi.org/10.1177/1724600819884722
Chen SW, et al. Expression of PD-1/PD-L1 in Head and Neck Squamous Cell Carcinoma and Its Clinical Significance. Int J Biol Markers. 2019;34(4):398-405. PubMed PMID: 31674884.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. AU - Chen,Shu-Wei, AU - Li,Si-Hao, AU - Shi,Ding-Bo, AU - Jiang,Wen-Mei, AU - Song,Ming, AU - Yang,An-Kui, AU - Li,Yu-Dong, AU - Bei,Jin-Xin, AU - Chen,Wen-Kuan, AU - Zhang,Quan, Y1 - 2019/11/01/ PY - 2019/11/2/pubmed PY - 2020/5/14/medline PY - 2019/11/2/entrez KW - Head and neck squamous cell carcinoma KW - P16 KW - prognosis KW - programmed death-1 KW - programmed death-ligand 1 SP - 398 EP - 405 JF - The International journal of biological markers JO - Int J Biol Markers VL - 34 IS - 4 N2 - OBJECTIVE: To investigate the role of programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and P16 in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: A total of 95 paraffin-embedded samples of tumorous tissue of HNSCC were collected. Expression levels of PD-1, PD-L1, and P16 were determined by immunohistochemistry. RESULTS: A significantly higher proportion of PD-1 among patients infected with the human papillomavirus was found. PD-L1 expression is closely associated with the primary site of the tumor, postoperative recurrence, survival, PD-1 expression and P16 expression. Univariable analysis indicated that T stage, N stage, tumor node metastasis stage, tumor differentiation, and PD-L1 expression were all shown to be prognostic variables for overall survival in patients with HNSCC. In the multivariate analysis, only N stage (P = 0.010) and PD-L1 expression (P = 0.001) were found to be independent prognostic variables for overall survival. In addition, for disease recurrence, multivariate analysis showed that only PD-L1 expression was the associated independent risk factor. For the patients with negative PD-L1 expression, Kaplan-Meier analysis revealed that they had significantly worse outcomes in terms of overall survival (P = 0.001). Similarly, compared with the patients with positive PD-L1 expression, those with negative PD-L1 expression had a higher probability of recurrence (P = 0.026). CONCLUSIONS: The expression of PD-L1, PD-1, and P16 in HNSCC is significantly correlated. Human papillomavirus infection (P16 positive) is negatively related to postoperative recurrence. HNSCC patients with positive PD-L1/PD-1 expression tend to have better overall survival outcomes and lower probability of recurrence, providing more evidence for the PD-l-targeted immunotherapy of HNSCC. SN - 1724-6008 UR - https://www.unboundmedicine.com/medline/citation/31674884/Expression_of_PD_1/PD_L1_in_head_and_neck_squamous_cell_carcinoma_and_its_clinical_significance_ L2 - https://journals.sagepub.com/doi/10.1177/1724600819884722?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -